CARA News and Press, Cara Therapeutics Inc. From 12/17/20

The opioid industry is an ~$50 billion annual business, but opioids are very harmful to the body and extremely addictive. CARA has a drug that is finishing its trials and expectation is that an NDA will be filed shortly, paving way for New Drug status and the ability to distribute. ...

Cannabis stocks are seeing catalyst movements upwards with the recent legalization of some 50% MoM; MJ ETF is not adequate in following the top stocks for cannabis; Putting together a portfolio with a tracker to follow upward movements in cannabis industry. For further detai...

Cara Therapeutics (CARA) has completed enrollment of its KARE Phase 2 dose-ranging trial evaluating oral Korsuva (difelikefalin tablets) for the treatment of moderate-to-severe pruritus (itchy skin) in atopic dermatitis patients. Topline data from this trial is expected in early 2021The ...

- Topline data expected in first half of 2021 - STAMFORD, Conn., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectivel...

STAMFORD, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, tod...

Image source: The Motley Fool. Cara Therapeutics Inc (NASDAQ: CARA) Q3 2020 Earnings Call Nov 9, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Cara Therapeutics Inc (CARA) Q3 2020 Earnings Call Transcript

Cara Therapeutics, Inc. (CARA) Q3 2020 Earnings Conference Call November 09, 2020 4:30 PM ET Company Participants Jack Hildick-Smith - Stern IR Derek Chalmers - President and CEO Thomas Reilly - CFO Conference Call Participants Zach Sachar - Piper Sandler Nick Rubino - Stifel Chi Meng Fong - ...

Cara Therapeutics (CARA): Q3 GAAP EPS of -$0.35 beats by $0.24.Revenue of $9.27M (+60.1% Y/Y) beats by $4.5M.Press Release For further details see: Cara Therapeutics EPS beats by $0.24, beats on revenue

– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by ...

STAMFORD, Conn., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announ...